for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Eisai Co., Ltd

4523.T

Latest Trade

5,550.00JPY

Change

8.00(+0.14%)

Volume

744,600

Today's Range

5,541.00

 - 

5,612.00

52 Week Range

5,205.00

 - 

10,805.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

U.S. FDA Says Announcing Project Orbis, An Initiative Of The FDA Oncology Center Of Excellence

Sept 17 (Reuters) - U.S. Food and Drug Administration::U.S. FDA SAYS ANNOUNCING PROJECT ORBIS, AN INITIATIVE OF THE FDA ONCOLOGY CENTER OF EXCELLENCE.FDA SAYS UNDER PROJECT, FDA, AUSTRALIAN THERAPEUTIC GOODS ADMINISTRATION & HEALTH CANADA REVIEWED APPLICATIONS FOR 2 ONCOLOGY DRUGS.FDA - UNDER PROJECT, FDA GRANTED ACCELERATED APPROVAL TO LENVIMA IN COMBINATION WITH KEYTRUDA FOR TREATMENT OF PATIENTS WITH ADVANCED ENDOMETRIAL CARCINOMA.

Eisai And Biogen To Discontinue Phase III Clinical Studies Of BACE Inhibitor Elenbecestat In Early Alzheimer's Disease

Sept 13 (Reuters) - Biogen Inc <BIIB.O>::EISAI AND BIOGEN TO DISCONTINUE PHASE III CLINICAL STUDIES OF BACE INHIBITOR ELENBECESTAT IN EARLY ALZHEIMER'S DISEASE.BIOGEN INC - DISCONTINUATION OF STUDIES BASED ON DATA SAFETY MONITORING BOARD RECOMMENDATION.BIOGEN INC - DECISION IS BASED ON RESULTS OF A SAFETY REVIEW CONDUCTED BY DATA SAFETY MONITORING BOARD.BIOGEN INC - AS PART OF THIS DECISION, LONG-TERM EXTENSION OF PHASE II CLINICAL TRIAL OF ELENBECESTAT (STUDY 202) WILL ALSO BE DISCONTINUED.BIOGEN INC - DSMB RECOMMENDED TO DISCONTINUE BACE INHIBITOR ELENBECESTAT IN EARLY ALZHEIMER'S DISEASE TRIALS DUE TO UNFAVORABLE RISK-BENEFIT RATIO.BIOGEN INC - DETERMINATION DOES NOT IMPACT PROGRAM OF ANTI-AMYLOID BETA (AΒ) PROTOFIBRIL MONOCLONAL ANTIBODY BAN2401.BIOGEN INC - PHASE III CLARITY AD TRIAL OF BAN2401 WILL CONTINUE..BIOGEN INC - INVESTIGATORS ARE BEING INFORMED OF DECISION, THEY WILL BE CONTACTING THEIR STUDY PARTICIPANTS TO DISCONTINUE INVESTIGATIONAL TREATMENT.

Merck And Eisai Receive Third Breakthrough Therapy Designation From FDA

July 23 (Reuters) - Merck & Co Inc <MRK.N>::MERCK AND EISAI RECEIVE THIRD BREAKTHROUGH THERAPY DESIGNATION FROM FDA FOR KEYTRUDA® (PEMBROLIZUMAB) PLUS LENVIMA® (LENVATINIB) COMBINATION TREATMENT.MERCK & CO INC- EFFICACY AND SAFETY OF COMBINATION OF KEYTRUDA PLUS LENVIMA HAS NOT BEEN ESTABLISHED.

Advanz Pharma Corp. Acquires International Rights To Two Medicines

April 1 (Reuters) - Advanz Pharma Corp <ADVZ.TO>::ADVANZ PHARMA CORP. ACQUIRES INTERNATIONAL RIGHTS TO TWO MEDICINES.ADVANZ PHARMA CORP - PROPOSED DEAL FOR $30 MILLION IN CASH PLUS APPROXIMATELY $3.3 MILLION FOR PURCHASED INVENTORY AND RELATED PREPAYMENTS..ADVANZ PHARMA CORP - ADVANZ PHARMA WILL PAY FOR ACQUISITION WITH CASH ON HAND..

Biogen, Eisai scrap Alzheimer's drug trials

March 21 (Reuters) - Biogen Inc <BIIB.O>::BIOGEN AND EISAI TO DISCONTINUE PHASE 3 ENGAGE AND EMERGE TRIALS OF ADUCANUMAB IN ALZHEIMER’S DISEASE.BIOGEN INC - INDEPENDENT DATA MONITORING COMMITTEE ADVISES ADUCANUMAB UNLIKELY TO MEET PRIMARY ENDPOINTS, LEADING TO DECISION TO DISCONTINUE TRIALS.BIOGEN INC - DECISION TO STOP TRIALS IS BASED ON RESULTS OF A FUTILITY ANALYSIS CONDUCTED BY AN INDEPENDENT DATA MONITORING COMMITTEE.BIOGEN - AS PART OF THIS DECISION, EVOLVE PHASE 2 SAFETY STUDY AND LONG-TERM EXTENSION OF PRIME PHASE1B STUDY OF ADUCANUMAB WILL ALSO BE DISCONTINUED.BIOGEN INC - RESULTS INDICATED TRIALS WERE UNLIKELY TO MEET PRIMARY ENDPOINT UPON COMPLETION.BIOGEN INC - INITIATION OF ADUCANUMAB PHASE 3 SECONDARY PREVENTION TRIAL WILL BE ASSESSED WHILE DATA FROM ENGAGE AND EMERGE ARE FURTHER EVALUATED.BIOGEN INC - RECOMMENDATION TO STOP STUDIES WAS NOT BASED ON SAFETY CONCERNS..BIOGEN INC - EVOLVE PHASE 2 SAFETY STUDY AND LONG-TERM EXTENSION OF PRIME PHASE1B STUDY OF ADUCANUMAB WILL ALSO BE DISCONTINUED.BIOGEN AND EISAI TO DISCONTINUE PHASE 3 ENGAGE AND EMERGE TRIALS OF ADUCANUMAB IN ALZHEIMER'S DISEASE.

Eisai & Imbrium Therapeutics Reports U.S. FDA Accepts New Drug Application For Lemborexant For Treatment Of Insomnia

March 11 (Reuters) - Eisai Co Ltd <4523.T>::EISAI AND IMBRIUM THERAPEUTICS ANNOUNCE U.S. FDA FILING ACCEPTANCE OF NEW DRUG APPLICATION FOR LEMBOREXANT FOR THE TREATMENT OF INSOMNIA.EISAI CO LTD - PDUFA DATE IS SET FOR DECEMBER 27, 2019.

FDA Accepts Eisai's Supplemental New Drug Application To Update Labeling For Anti-Obesity Agent Belviq

Feb 25 (Reuters) - Eisai Co Ltd <4523.T>::FDA ACCEPTS EISAI'S SUPPLEMENTAL NEW DRUG APPLICATION (SNDA) TO UPDATE THE LABELING FOR ANTI-OBESITY AGENT BELVIQ® (LORCASERIN HCL).EISAI INC - PROPOSED UPDATED LABEL FOR BELVIQ TO INCLUDE LONG-TERM EFFICACY AND SAFETY DATA FROM CAMELLIA-TIMI 61.

Eisai Co Ltd Announces Results Of First Round Of Voluntary Retirement Program

Eisai Co Ltd <4523.T>::EISAI CO LTD ANNOUNCES RESULTS OF FIRST ROUND OF VOLUNTARY RETIREMENT PROGRAM.

Eisai Inc Says Eisai Co Ltd, Purdue Pharma Announced A NDA Has Been Submitted To U.S. FDA For Lemborexant

Jan 15 (Reuters) - Eisai Co Ltd <4523.T>::EISAI INC SAYS EISAI CO LTD, PURDUE PHARMA LP ANNOUNCED A NDA HAS BEEN SUBMITTED TO U.S. FDA FOR LEMBOREXANT, SEEKING APPROVAL FOR TREATING INSOMNIA.

Eisai And Biogen Announce Additional Data From The Phase II Clinical Trial Of Ban2401

Oct 25 (Reuters) - Biogen Inc <BIIB.O>::EISAI AND BIOGEN ANNOUNCE PRESENTATION OF ADDITIONAL DATA FROM THE PHASE II CLINICAL TRIAL OF BAN2401 IN EARLY ALZHEIMER’S DISEASE AT THE 2018 CLINICAL TRIALS ON ALZHEIMER’S DISEASE (CTAD) CONFERENCE.EISAI AND BIOGEN ANNOUNCE PRESENTATION OF ADDITIONAL DATA FROM THE PHASE II CLINICAL TRIAL OF BAN2401 IN EARLY ALZHEIMER’S DISEASE AT THE 2018 CLINICAL TRIALS ON ALZHEIMER’S DISEASE (CTAD) CONFERENCE.BIOGEN INC - BAN2401 DEMONSTRATED AN ACCEPTABLE TOLERABILITY PROFILE THROUGH 18 MONTHS OF STUDY DRUG ADMINISTRATION.BIOGEN INC - EISAI AND BIOGEN ARE CURRENTLY DISCUSSING NEXT STEPS FOR BAN2401 WITH REGULATORY AUTHORITIES.BIOGEN INC - AN OPEN-LABEL EXTENSION FOR PATIENTS PREVIOUSLY ENROLLED IN STUDY 201 IS BEING PLANNED, WITH ENROLLMENT EXPECTED TO BEGIN THIS YEAR.BIOGEN - HIGHEST TREATMENT DOSE SHOWED STATISTICALLY SIGNIFICANT SLOWING OF CLINICAL DECLINE ON ADCOMS OF 30 PERCENT VERSUS PLACEBO AT 18 MONTHS.BIOGEN - FROM CONVENTIONAL ANALYSIS, HIGHEST TREATMENT DOSE DEMONSTRATED STATISTICALLY SIGNIFICANT REDUCTION IN BRAIN AMYLOID AT 18 MONTHS (P<0.0001).BIOGEN INC - BAN2401 DEMONSTRATED AN ACCEPTABLE TOLERABILITY PROFILE THROUGH 18 MONTHS OF STUDY DRUG ADMINISTRATION.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up